Disease management
Cardiac and lung-disease platform Eko Health secured $41 million in Series D funding.
Cancer patients and caregivers will receive free access to an AI-enabled app for mental health and other support services.
The company will use the funds to expand its cloud-based automation platform for providers and pharmaceutical companies.
The South Korean company now plans to expand the application of its AI to diagnose other medical conditions, including heart and neurological disorders.
The continuous glucose monitoring biosensor platform will use the funds to scale its manufacturing, move toward regulatory approval and perform more clinical trials.
Also, Lunit has completed its acquisition of breast screening AI company Volpara.
Also, Optiscan is working with Mayo Clinic to develop a digital endomicroscopic imaging system for robotic surgery.
The organizations will codevelop an atrial fibrillation program that provides clinical decision support tools and patient coaching between clinical visits.
The companies will utilize Flatiron Clinical Pipe to connect electronic health records to electronic data capture for clinical trial data gathering.
It will validate BrainEye's 60-second eye movement test to about 500 participants.